PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

被引：0
|
作者：
Hu, Xichun
Cao, Jun
Teng, Yue'e
Li, Hui-Ping
Zhang, Lili
Ouyang, Quchang
Xie, Weimin
Pan, Yueyin
Song, Zhenchuan
Ling, Xiaoling
Wu, Xiaohong
Xu, Jingwei
Li, Li
Ren, Liping
Wang, Hong
Zhou, Dongxian
Luo, Jing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-43
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
    Yin, Wenjin
    Wang, Yaohui
    Wu, Ziping
    Ye, Yumei
    Zhou, Liheng
    Xu, Shuguang
    Lin, Yanping
    Du, Yueyao
    Yan, Tingting
    Yang, Fan
    Zhang, Jie
    Liu, Qiang
    Lu, Jinsong
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3677 - 3685
  • [32] Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.
    Ma, Fei
    Li, Qiao
    Guan, Xiuwen
    Chen, Shanshan
    Yi, Zongbi
    Lan, Bo
    Xing, Puyuan
    Fan, Ying
    Wang, Jiayu
    Luo, Yang
    Yuan, Peng
    Cai, Ruigang
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
    Gori, Stefania
    Inno, Alessandro
    Rossi, Valentina
    Turazza, Monica
    Fiorio, Elena
    Fabi, Alessandra
    Bisagni, Giancarlo
    Foglietta, Jennifer
    Santini, Daniele
    Pavese, Ida
    Pellegrino, Arianna
    Zambelli, Alberto
    Vici, Patrizia
    Leonardi, Vita
    Barni, Sandro
    Saracchini, Silvana
    Bogina, Giuseppe
    Marchetti, Fabiana
    Duranti, Simona
    Lunardi, Gianluigi
    Montemurro, Filippo
    PLOS ONE, 2016, 11 (05):
  • [34] Pyrotinib as a therapeutic for HER2-positive breast cancer
    Kioutchoukova, Ivelina
    Lucke-Wold, Brandon P.
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) : 1376 - 1379
  • [35] Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
    Kaufman, Bella
    Stein, Steven
    Casey, Michelle A.
    Newstat, Beth O.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 61 - 65
  • [36] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [37] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
  • [38] Neoadjuvant pyrotinib versus pertuzumab in combination with trastuzumab and nab-Paclitaxel for patients with HER2-positive early or locally advanced breast cancer (Pyramid): A randomized, multicenter, open-label, phase 2 trial
    Zhang, Jin
    Liu, Qiang
    Jiang, Hongchuan
    Zhang, Jianguo
    Ou, Jianghua
    Chen, Dedian
    Tian, Fuguo
    Li, Yongqing
    Cheng, Xiaoming
    Ouyang, Zhong
    CANCER RESEARCH, 2022, 82 (04)
  • [39] A Phase Ib/II Study of anlotinib combined with pyrotinib and capecitabine for HER2-Positive Metastatic Breast Cancer
    Luo, Ting
    Zhong, Xiaorong
    Chen, Jie
    CANCER RESEARCH, 2023, 83 (05)
  • [40] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345